Latest Licensing News

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Blackstone Minerals has cleared a key regulatory hurdle at its Mankayan Copper-Gold Project, lifting a Cease and Desist Order and initiating a Pre-Feasibility Study. The company also strengthened its board with mining veteran Mark Williams and reported a solid cash position of $14.6 million.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Caravel Minerals has secured critical tenure and advanced engineering designs for its Caravel Copper Project, alongside non-binding debt interest of up to USD 220 million from European export credit agencies.

NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.

Gold Hydrogen is poised to begin flow testing at its Ramsay Project, targeting separate Natural Hydrogen and Helium zones, while advancing green methanol and helium commercialisation studies amid robust market demand.

dorsaVi has launched a multi-year partnership with Taiwan’s ITRI and NTU to develop its proprietary RRAM platform at the 22-nm node, complemented by a new advisory board and neuromorphic IP acquisition, positioning the company at the forefront of ultra-edge AI hardware.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Alara Resources maintained steady copper-gold production at its Al Wash-hi Majaza Mine despite regional geopolitical shipping disruptions, while advancing exploration and managing ongoing legal proceedings in Oman.